glp 1 agonist drug List of approved and pending GLP-1 medications Issue 42: GLP-1 RA Drug
Description
GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
however, trials developed mainly to evaluate the long-term impact of tirzepatide on cardiovascular events, including stroke, are currently in progress [42]
27 This is in contrast to exenatide, which is primarily eliminated through the kidneys, and is not recommended for use in patients with severe renal impairment or in those with end-stage renal disease (ESRD)
Liraglutide could also improve hepatic steatosis and ballooning degeneration in patients with NASH (192)
Cao C, Yang S, Zhou Z
